These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21330486)

  • 1. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
    Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma sTWEAK and PTX3: New determinant tools of cardiovascular outcome also in patients with CKD.
    Meier P
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):697-9. PubMed ID: 21441127
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
    Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.
    Yilmaz MI; Carrero JJ; Ortiz A; Martín-Ventura JL; Sonmez A; Saglam M; Yaman H; Yenicesu M; Egido J; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1716-23. PubMed ID: 19820131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients.
    Fan WC; Huang CC; Yang YY; Lin A; Lee KC; Hsieh YC; Fung CP; Hsu HC; Hou MC; Lin HC
    J Microbiol Immunol Infect; 2017 Dec; 50(6):905-914. PubMed ID: 26872435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes.
    Yilmaz MI; Stenvinkel P; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Altun B; Yenicesu M; Carrero JJ
    Nephrol Dial Transplant; 2011 Nov; 26(11):3537-43. PubMed ID: 21378154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
    Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease.
    Yilmaz MI; Sonmez A; Qureshi AR; Saglam M; Stenvinkel P; Yaman H; Eyileten T; Caglar K; Oguz Y; Taslipinar A; Vural A; Gok M; Unal HU; Yenicesu M; Carrero JJ
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1617-25. PubMed ID: 21700826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.
    Carrero JJ; Ortiz A; Qureshi AR; Martín-Ventura JL; Bárány P; Heimbürger O; Marrón B; Metry G; Snaedal S; Lindholm B; Egido J; Stenvinkel P; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):110-8. PubMed ID: 18945991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe periodontitis is linked with increased peripheral levels of sTWEAK and PTX3 in chronic migraineurs.
    Leira Y; Ameijeira P; Domínguez C; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; D'Aiuto F; Leira R; Blanco J
    Clin Oral Investig; 2020 Feb; 24(2):597-606. PubMed ID: 31111284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients.
    Hassan SB; El-demery AB; Ahmed AI; Abukhalil RE
    Arab J Nephrol Transplant; 2012 Jan; 5(1):27-32. PubMed ID: 22283863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.
    Carrero JJ; Kyriazis J; Sonmez A; Tzanakis I; Qureshi AR; Stenvinkel P; Saglam M; Stylianou K; Yaman H; Taslipinar A; Vural A; Gok M; Yenicesu M; Daphnis E; Yilmaz MI
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):207-15. PubMed ID: 22193237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between IL-10 levels and cardiovascular events in patients with CKD.
    Yilmaz MI; Solak Y; Saglam M; Cayci T; Acikel C; Unal HU; Eyileten T; Oguz Y; Sari S; Carrero JJ; Stenvinkel P; Covic A; Kanbay M
    Clin J Am Soc Nephrol; 2014 Jul; 9(7):1207-16. PubMed ID: 24789549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly.
    Sjöberg B; Qureshi AR; Heimbürger O; Stenvinkel P; Lind L; Larsson A; Bárány P; Ärnlöv J
    J Intern Med; 2016 Feb; 279(2):173-9. PubMed ID: 26355706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
    Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
    Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
    J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.
    Yilmaz MI; Axelsson J; Sonmez A; Carrero JJ; Saglam M; Eyileten T; Caglar K; Kirkpantur A; Celik T; Oguz Y; Vural A; Yenicesu M; Lindholm B; Stenvinkel P
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):535-41. PubMed ID: 19211665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients.
    Turkmen K; Tonbul HZ; Erdur FM; Toker A; Biyik Z; Ozbiner H; Gaipov A; Gul EE; Kayrak M; Solak Y; Ozbek O; Turk S; Covic A
    BMC Nephrol; 2013 Jul; 14():144. PubMed ID: 23849432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentraxin 3 (PTX3): A Molecular Marker of Endothelial Dysfunction in Chronic Migraine.
    Domínguez-Vivero C; Leira Y; López-Ferreiro A; Saavedra M; Rodríguez-Osorio X; Sobrino T; Campos F; Castillo J; Leira R
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32244987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients.
    Banerjee D; Recio-Mayoral A; Chitalia N; Kaski JC
    Clin Cardiol; 2011 Jun; 34(6):360-5. PubMed ID: 21538390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.